<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bryce Foster | Beck Mead | Activity</title>
	<link>https://brycefoster.com/members/manpath00/activity/</link>
	<atom:link href="https://brycefoster.com/members/manpath00/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Beck Mead.</description>
	<lastBuildDate>Thu, 11 Jun 2026 10:30:55 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">c697967545502d9828dde36f477c2df2</guid>
				<title>Beck Mead posted an update: Understanding Fentanyl Citrate Sublingual Tablets in the UK: [&#133;]</title>
				<link>https://brycefoster.com/activity/p/1643074/</link>
				<pubDate>Tue, 12 May 2026 08:03:02 +0000</pubDate>

									<content:encoded><![CDATA[<p>Understanding Fentanyl Citrate Sublingual Tablets in the UK: A Clinical Overview</p>
<p>Discomfort management remains one of the most complicated areas of contemporary medicine, especially when dealing with the needs of patients with chronic, life-limiting illnesses. In the United Kingdom, Fentanyl Citrate sublingual tablets have emerged as a crucial&hellip;<span class="activity-read-more" id="activity-read-more-1643074"><a href="https://brycefoster.com/activity/p/1643074/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">41cc657614be4d75c9234945e38032bb</guid>
				<title>Beck Mead became a registered member</title>
				<link>https://brycefoster.com/activity/p/1643065/</link>
				<pubDate>Tue, 12 May 2026 08:01:49 +0000</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>